Achillion Pharmaceuticals Inc (NASDAQ:ACHN)
During the Trading Day
| 7.64 |  -0.10 / -1.29% |
Data as of 4:00pm ET | Day’s Change |
During After-Hours Switch to standard view »
| 7.64 |  0.00 / 0.00% |
Volume: 19.0K |
Latest ACHN News | Press Releases
No recent news for Achillion Pharmaceuticals Inc.
Today’s Trading
| Previous close | 7.74 |
| Today’s open | 7.66 |
| Day’s range | 7.44 - 7.77 |
| Volume | 899,909 |
| Average volume (3 months) | 1,111,898 |
| Market cap | $747.4M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/23/2013
Growth & Valuation
| Earnings growth (last year) | +7.25% |
| Earnings growth (this year) | -1.90% |
| Earnings growth (next 5 years) | +4.57% |
| Revenue growth (last year) | +955.47% |
| P/E ratio | NM |
| Price/Sales | 227.26 |
| Price/Book | 8.55 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| AUXLAuxilium Pharmaceuti... | +0.02 | +0.13% |
| CBPOChina Biologic Produ... | +0.10 | +0.38% |
| OPTROptimer Pharmaceutic... | +0.29 | +2.02% |
| NBIXNeurocrine Bioscienc... | +0.70 | +5.83% |
Data as of 4:00pm ET, 05/23/2013
Financials
| Next reporting date | August 7, 2013 |
| EPS forecast (this quarter) | -$0.15 |
| Annual revenue (last year) | $2.6M |
| Annual profit (last year) | -$47.1M |
| Net profit margin | -1,807.71% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Michael D. Kishbauch, MBA |
CFO, Secretary, SVP & Head-Investor Relations Mary Kay Fenton, MBA, CPA |
Corporate headquarters New Haven, Connecticut |
Forecasts
